CPC C12Q 1/6883 (2013.01) [C12Q 1/686 (2013.01); C12Q 1/6813 (2013.01); C12Q 1/6851 (2013.01); C12Q 1/6876 (2013.01); G01N 33/502 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); G01N 2800/224 (2013.01)] | 26 Claims |
1. A method for analyzing a sample, comprising:
(i) providing a biological sample obtained from a subject having, suspected of having, or being at risk for hereditary angioedema (HAE);
(ii) measuring the level of a RNA biomarker set, wherein the RNA biomarker set comprises a messenger RNA encoding mitochondrially-encoded cytochrome C oxidase III (MT-CO3);
(iii) identifying the subject as a subject having HAE based on the level of the RNA biomarker set, an increase of the level of MT-CO3 of the subject from that of a control subject being indicative of the subject having HAE; and
(iv) administering to the subject identified as having HAE in step (iii) an effective amount of a therapeutic agent for treating HAE;
wherein the therapeutic agent is a plasma kallikrein (pKal) inhibitor, a bradykinin 2 receptor (B2R) inhibitor, and/or a Cl esterase inhibitor.
|